S890
Clinical - Mixed sites & palliation
ESTRO 2026
Digital Poster 3065
were significantly associated with poorer survival. Together these factors explained 19% of the variance. The presence of extracranial metastases was not significantly correlated with survival but showed a significant positive association with the number of BM.
Current Practices of Hypofractionation in Proton Therapy: Results from a European Multi-Center Survey Daniela Alterio 1 , Maria Giulia Vincini 1 , Luca Bergamaschi 1 , Floriana Pansini 1 , Christian Karger 2 , Marcus Stocks 3 , Cai Grau 4 , Damien Weber 5 , Dietmar Georg 6 , Johannes Albertus Langendijk 7 , Karin Haustermans 8 1 Radiation Oncology, IEO, IRCCS, Milan, Italy. 2 Division Medical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 3 EBG MedAustron GmbH, Marie Curie-Straße 5, A-2700, Vienna, Austria. 4 Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark. 5 Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland. 6 Department of Radiation Oncology, Medical University of Vienna, vienna, Austria. 7 Radiation Oncology, University Medical Centre Groningen, Groningen, Netherlands. 8 8. Department of Radiation Oncology, University
Conclusion: Over half of the patients treated with SRS for BM and according to contemporary systemic intervention, survived beyond one year - challenging the historically poor survival reported in this population.Baseline factors included in previous prediction models are still relevant, although they explained only part of the variability, indicating additional factors, such as molecular factors, contribute to patient outcomes. Importantly, presence of extracranial metastases showed no correlation with survival.These findings highlight the growing population of long-term survivors and the urgent need to understand and address the broad, long-term effects of treatment on both physical health and mental well-being, while ensuring optimal follow-up care. References: 1. Nederlandse Vereniging voor Neurologie. Hersenmetastasen.; 2025. Accessed September 1, 2025. https://richtlijnendatabase.nl/richtlijn/hersenmetastas en/startpagina_-_hersenmetastasen.html 2. Tabouret E, Chinot O, Metellus P, Tallet A, Viens P, Goncalves A. Recent Trends in Epidemiology of Brain Metastases: An Overview.; 2012.3. Brenner AW, Patel AJ. Review of Current Principles of the Diagnosis and Management of Brain Metastases. Front Oncol.Frontiers Media S.A. 2022;12. doi:10.3389/fonc.2022.8576224. Aizer AA, Lamba N, Ahluwalia MS, et al. Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Neuro Oncol. 2022;24(10):1613-1646. doi:10.1093/neuonc/noac118 Keywords: long-term survivors (LTS), brain metastases (BM)
Hospitals Leuven, Leuven, Belgium
Purpose/Objective: Hypofractionation offers several advantages, e.g. reduced treatment time, improved cost-effectiveness, and enhanced patient convenience. However, its role in proton therapy (PT) remains uncertain due to limited clinical evidence and lack of consensus on optimal indications and schedules. The present survey -promoted within the Work Package 1 of European Particle Therapy Network (EPTN) - aimed to capture the current patterns of practice perspectives on hypofractionation in proton therapy (HYPO-PT) in Europe. Material/Methods: For the purpose of the survey, HYPO-PT was defined as a dose/fraction >2.5 Gy(RBE); only curative treatments were considered. The questionnaire consisted of 44 questions divided into four sections: 1) general information, 2) HYPO-PT in your clinical practice, 3) Technical Considerations, 4) future perspective. The survey was administered via Google Forms to Medical Directors of all 23 contacted PT centers in Europe from 14th April to 30th October 2025. Collected data were centrally analyzed at the European Institute of Oncology. Results: Eighteen (78%) centers participated. The majority (89%) use HYPO-PT in their daily clinical practice for adult patients. Among them, the majority (69%, 11 centers) treat less than 25% of adult patients with HYPO-PT schedule. Eight (45%) and 5 (28%) centers treat less than 50 patients/year and 50-100
Made with FlippingBook - Share PDF online